These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 30027617)

  • 1. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
    Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
    Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma.
    Zhang C; Zhang Z; Li F; Shen Z; Qiao Y; Li L; Liu S; Song M; Zhao X; Ren F; He Q; Yang B; Fan R; Zhang Y
    Oncoimmunology; 2018; 7(11):e1461304. PubMed ID: 30377558
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A machine learning analysis of a "normal-like" IDH-WT diffuse glioma transcriptomic subgroup associated with prolonged survival reveals novel immune and neurotransmitter-related actionable targets.
    Nguyen HD; Allaire A; Diamandis P; Bisaillon M; Scott MS; Richer M
    BMC Med; 2020 Oct; 18(1):280. PubMed ID: 33059718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status.
    Li G; Wang Z; Zhang C; Liu X; Yang F; Sun L; Liang J; Hu H; Liu Y; You G; Bao Z; Zhang W; Wang Z; Jiang T
    Dis Markers; 2018; 2018():5975216. PubMed ID: 29887919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
    Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
    Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
    Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
    J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of DNA methylation in adult diffuse gliomas.
    Aoki K; Natsume A
    Brain Tumor Pathol; 2019 Apr; 36(2):84-91. PubMed ID: 30937703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.
    Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z
    Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas.
    Huang GH; Du L; Li N; Zhang Y; Xiang Y; Tang JH; Xia S; Zhang EE; Lv SQ
    Cancer Lett; 2018 Sep; 432():93-102. PubMed ID: 29885519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.
    Zhou Z; Luther N; Ibrahim GM; Hawkins C; Vibhakar R; Handler MH; Souweidane MM
    J Neurooncol; 2013 Feb; 111(3):257-64. PubMed ID: 23232807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
    Röver LK; Gevensleben H; Dietrich J; Bootz F; Landsberg J; Goltz D; Dietrich D
    EBioMedicine; 2018 Feb; 28():97-104. PubMed ID: 29396294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Type of IDH-wildtype Glioma Characterized by Gliomatosis Cerebri-like Growth Pattern, TERT Promoter Mutation, and Distinct Epigenetic Profile.
    Muench A; Teichmann D; Spille D; Kuzman P; Perez E; May SA; Mueller WC; Kombos T; Nazari-Dehkordi S; Onken J; Vajkoczy P; Ntoulias G; Bettencourt C; von Deimling A; Paulus W; Heppner FL; Koch A; Capper D; Kaul D; Thomas C; Schweizer L
    Am J Surg Pathol; 2023 Dec; 47(12):1364-1375. PubMed ID: 37737691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.